Exploring synthetic and therapeutic prospects of new thiazoline derivatives as aldose reductase (ALR2) inhibitors†

Muhammad Tariq Shehzad,‡ a Aqeel Imran, b Abdul Hameed, b,c g Mariya al Rashida, c,d Marium Bibi, e Maliha Uroos, f Asnuzilawati Asari, f Shafia Iftikhar, f Habsah Mohamad, h Muhammad Nawaz Tahir, i Zahid Shafiq*a and Jamshed Iqbal f,b

Inhibition of aldose reductase (ALR2) by using small heterocyclic compounds provides a viable approach for the development of new antidiabetic agents. With our ongoing interest towards aldose reductase (ALR2) inhibition, we have synthesized and screened a series of thiazoline derivatives (5a–k, 6a–f, 7a–l & 8a–j) to find a lead as a potential new antidiabetic agent. The bioactivity results showed the thiazoline-based compound 7b having a benzyl substituent and nitrophenyl substituent-bearing compound 8e were identified as the most potent molecules with IC50 values of 1.39 ± 2.21 μM and 1.52 ± 0.78 μM respectively compared with the reference sorbinil with an IC50 value of 3.14 ± 0.02 μM. Compound 7b with only 23.4% inhibition for ALR1 showed excellent selectivity for the targeted ALR2 to act as a potential lead for the development of new therapeutic agents for diabetic complications.

1 Introduction

The incidence of Diabetes mellitus (DM) disease is increasing alarmingly and more than 400 million people are affected all over the world. Diabetes complications affect about 25% of the elderly population over the age of 65, and this proportion is steadily growing. The majority of the population affected with DM belongs to under-developed or developing regions of the world. According to a recent study between COVID-19 and diabetes, the COVID-19 patients with diabetes have a two-fold higher risk of mortality and disease incidence than COVID-19 patients without diabetes [00]. In case of progression of this disease severe diabetic complications result such as neuropathy, nephropathy, mood disorders, diabetic retinopathy. These complications are generally a result of hyperglycemia† which initiates the polyol pathway due to non-insulin dependent glucose uptake. This pathway primarily involves NADPH dependent reduction of glucose to sorbitol, the enzyme responsible for this reduction is aldose reductase (AR; ALR2; EC 1.1.1.21) belonging to aldo-keto reductase enzyme superfamily. The sorbitol in turn converts metabolically via another enzyme sorbitol dehydrogenase into fructose, resulting in increase in the glucose flux. High glucose level in diabetes promotes the combination of glucose to ALR2 and metabolized about one third of the total glucose to sorbitol via the polyol pathway in tissues such as retina, lens, peripheral nerves and kidneys. As a result, the regulated polyol pathway accumulates the sorbitol in cells causing swelling of cell, osmotic imbalance and changes in permeability of membrane. Sorbitol does not penetrate the cellular membranes especially that of eye lens. Moreover, the drastic lessening of NAD† and NADPH alters the cellular redox potentials and weakens the enzymatic activities like that of glutathione reductase and nitric oxide synthase (NOS); worsening the intracellular oxidative stress level. Stress level is also increased via free radicals produced from a number of radical precursors like protein kinase C (PKC) isomer, advanced glycation end products (AGEs), poly-ADP-ribose polymerase (PARP) and mitogen-activated protein kinase (MAPK). High level of free radicals damages a number of tissues. Hence, all the oxidative stress reactions mediated by ALR2 along with the polyol pathway represent important pathogenesis of diabetic complications.†
From aldol-keto reductase (AKR), those reducing the aldehydes are called aldehyde reductases (ALR1, EC 1.1.1.2) while those involved in the reduction of ketones are termed as ketoreductases (also belonging to AKR family). Both enzymes have almost similar structure differing just in their active sites. 10

The one accurately capable to reduce the aldehyde functionality of glucose in polyol pathway is ALR1. This enzyme is also involved in metabolism of 3-deoxyglucosone and methyl glyoxal causing toxic glycation end products. In contrast, it also assists the reductive detoxification of reactive aldehydes. An example is the reduction of aldehyde phospholipids to regulate the pro-inflammatory response. 11

There are a number of studies reported the aldose reductase inhibitors (ARIs). 12–17 Up to yet now, only one ARI drug; Epalrestat, ONO Pharmaceutical, Osaka, Japan has been marketed. 18,19 Though the polyol pathway inhibition is more challenging to reduce the complications of diabetes; some isolated natural products have been used as potent ARIs. Some synthesized compounds have same active functionalities as that of potent natural product and have been entered in to clinical trials (Fig. 1). It is of utmost importance to develop potent and selective ARIs (ALR1 and ALR2 share about 65% sequence homology), which can regulate the polyol pathway and combat secondary diabetic complications. 20,21 The present work focuses on the synthesis of a series of novel thiazoline based inhibitors and their evaluation as ARIs.

The compounds containing benzoazinone, adamantyl, benzodioxane and indole nuclei have been synthesized and investigated for their diverse biological activities as many of these moieties are also the part of bioactive natural products. 22–33 Incorporation or conjugation of thiazoline moieties with another biologically important nucleus is expected to enhance their biological potential. In view of this and in search of novel bioactive molecules, the study was designed and aimed to prepare a number of various thiazolines possessing benzoazinone, adamantyl, benzodioxane and indole moieties to evaluate their enzyme inhibition potential with an expectation that they may display more potent activity and thus result into the development of different compounds of medicinal interest.

2. Results and discussion

2.1 Chemistry of thiazolines derivatives 5a–k, 6a–f, 7a–i and 8a–j

In the current study, the thiazoline derivatives 5–8 were designed and prepared in variable yields (76–92%) by using four different types of carbonyl group bearing compounds 1 i.e. 6-acetyl-2H-benzo[b][1,4]oxazin-3(4H)-one, 1-acetyl adamantane, 1,4-benzodioxan-6-yl methyl ketone and indole-3-carboxaldehyde. The starting materials bearing carbonyl group were treated in equimolar quantities with N-substituted thiosemicarbazides 2 in methanol as solvent. The reaction was catalyzed by using glacial acetic acid as catalyst to get thiosemicarbazones 3 as intermediate. 34,35 Further, the thiosemicarbazone derivatives 3 were reacted with a range of 4-substituted 2-bromoacetophenones 4 in solvent ethanol along with sodium acetate. The resulting mixture was heated at reflux till the complete consumption of starting material, monitored by TLC analysis. The pure product was obtained via recrystallization from absolute ethanol (Scheme 1).

The structures of thiazoline derivatives (5a–k, 6a–f, 7a–i and 8a–j) were confirmed by using different spectroscopic...
techniques that include IR spectra, NMR spectroscopy and microanalysis (CHN). The infrared spectra of a typical thiazoline from 5a–k series showed a stretching band of NH group at 3184–3338 cm$^{-1}$, carbonyl group (C=O) of lactam moiety at 1663–1748 cm$^{-1}$ and imine group C=N bands were appeared at 1578–1593 cm$^{-1}$ regions consequently, the compounds in
| Compound | R     | R<sub>1</sub> | R<sub>2</sub> | X    |
|----------|-------|--------------|--------------|------|
| 5a       |       | CH<sub>3</sub> C<sub>6</sub>H<sub>5</sub> | Br           |
| 5b       |       | CH<sub>3</sub> 3-OCH<sub>3</sub>C<sub>6</sub>H<sub>4</sub> | Br           |
| 5c       |       | CH<sub>3</sub> 2,6-(CH<sub>3</sub>)<sub>2</sub>C<sub>6</sub>H<sub>3</sub> | Br           |
| 5d       |       | CH<sub>3</sub> 2-CH<sub>3</sub>C<sub>6</sub>H<sub>4</sub> | Br           |
| 5e       |       | CH<sub>3</sub> C<sub>6</sub>H<sub>5</sub> | NO<sub>2</sub> |
| 5f       |       | CH<sub>3</sub> 3-OCH<sub>3</sub>C<sub>6</sub>H<sub>4</sub> | NO<sub>2</sub> |
| 5g       |       | CH<sub>3</sub> 4-FC<sub>6</sub>H<sub>4</sub> | NO<sub>2</sub> |
| 5h       |       | CH<sub>3</sub> 2,6-(CH<sub>3</sub>)<sub>2</sub>C<sub>6</sub>H<sub>3</sub> | NO<sub>2</sub> |
| 5i       |       | CH<sub>3</sub> C<sub>6</sub>H<sub>5</sub> | Cl           |
| 5j       |       | CH<sub>3</sub> 3-OCH<sub>3</sub>C<sub>6</sub>H<sub>4</sub> | Cl           |
| 5k       |       | CH<sub>3</sub> 4-FC<sub>6</sub>H<sub>4</sub> | Cl           |
| 5l       |       | CH<sub>3</sub> C<sub>6</sub>H<sub>5</sub> | Br           |
| 5m       |       | CH<sub>3</sub> 3-OCH<sub>3</sub>C<sub>6</sub>H<sub>4</sub> | Br           |
| 5n       |       | CH<sub>3</sub> 4-FC<sub>6</sub>H<sub>4</sub> | Br           |
| 5o       |       | CH<sub>3</sub> C<sub>6</sub>H<sub>5</sub> | Cl           |
| 5p       |       | CH<sub>3</sub> 3-OCH<sub>3</sub>C<sub>6</sub>H<sub>4</sub> | Cl           |
| 5q       |       | CH<sub>3</sub> 4-FC<sub>6</sub>H<sub>4</sub> | Cl           |
| 5r       |       | CH<sub>3</sub> C<sub>6</sub>H<sub>5</sub> | Br           |
| 5s       |       | CH<sub>3</sub> 3-OCH<sub>3</sub>C<sub>6</sub>H<sub>4</sub> | Br           |
| 5t       |       | CH<sub>3</sub> 4-FC<sub>6</sub>H<sub>4</sub> | Br           |
| 5u       |       | CH<sub>3</sub> C<sub>6</sub>H<sub>5</sub> | Cl           |
| 5v       |       | CH<sub>3</sub> 3-OCH<sub>3</sub>C<sub>6</sub>H<sub>4</sub> | Cl           |
| 5w       |       | CH<sub>3</sub> 4-FC<sub>6</sub>H<sub>4</sub> | Cl           |

**Table 1** Thiazoline derivatives 5a–k, 6a–f, 7a–i and 8a–j

**Table 1 (Contd.)**
The proton $^1$H-NMR spectra of different thiazoline series 6a–f and 7a–i, showed imine group (C=NR) in the range of 1558–1617 cm$^{-1}$. Furthermore, the indole-based thiazolines 8a–j, showed NH stretching band at 3125–3444 cm$^{-1}$ while C=NR bond in the range of 1603–1615 cm$^{-1}$.

The proton $^1$H-NMR spectra of different thiazoline series 5a–k and 8a–j, displayed broad singlets for lactam NH and indole NH.
Table 2  
*In vitro* inhibitory activity of thiazoline derivatives against Aldehyde (ALR1) and Aldose (ALR2) reductase enzymes

| Code | Structure | ALR2 IC50 (mM) | SEM % | ALR1 IC50 (mM) | SEM % | Percent inhibition |
|------|-----------|----------------|-------|----------------|-------|--------------------|
| 5a   | ![Structure](image1) | 13.4% | 22.6% |
| 5b   | ![Structure](image2) | 27.4% | 31.9% |
| 5c   | ![Structure](image3) | 22.7% | 12.4% |
| 5d   | ![Structure](image4) | 19.5% | 6.7% |
| 5e   | ![Structure](image5) | 20.83% | 31.4% |
| 5f   | ![Structure](image6) | 3.13 ± 1.45 | 3.24 ± 2.72 |
Table 2 (Contd.)

| Code | Structure | ALR2 IC₅₀ (µM) ± SEM | Percent inhibition |
|------|-----------|---------------------|--------------------|
| 5g   | ![Structure 5g](image1) | 31.73% | 24.7% |
| 5h   | ![Structure 5h](image2) | 18% | 19.6% |
| 5i   | ![Structure 5i](image3) | 16.77% | 31.3% |
| 5j   | ![Structure 5j](image4) | 5.16% | 32.8% |
| 5k   | ![Structure 5k](image5) | 35.19% | 22.6% |
| 6a   | ![Structure 6a](image6) | 4.40 ± 1.45 | 3.29 ± 1.47 |
| Code | Code Structure | ALR2 \( \text{IC}_{50} \) (\( \mu \text{M} \)) ± SEM | ALR1 \% Percent inhibition |
|------|---------------|-----------------------------|-----------------------------|
| 6b   | ![Image](image1.png) | 12.9 ± 0.39 | 4.93 ± 1.86 |
| 6c   | ![Image](image2.png) | 10.19 ± 1.35 | 4.07 ± 2.35 |
| 6d   | ![Image](image3.png) | 4.21 ± 2.35 | 11.6% |
| 6e   | ![Image](image4.png) | 2.18 ± 0.83 | 33.5% |
| 6f   | ![Image](image5.png) | 3.51 ± 2.31 | 19.7% |
| Code | Structure | ALR2 | ALR1 |
|------|-----------|------|------|
| 7a   | ![Structure 7a](image) | 5.96 ± 1.05 | 23.7% |
| 7b   | ![Structure 7b](image) | 1.39 ± 2.21 | 23.4% |
| 7c   | ![Structure 7c](image) | 3.14 ± 1.87 | 33.4% |
| 7d   | ![Structure 7d](image) | 11% | 4.5% |
| 7e   | ![Structure 7e](image) | 14% | 23.6% |
| 7f   | ![Structure 7f](image) | 23% | 21.7% |
Table 2 (Contd.)

| Code | Structure | ALR2 IC₅₀ (μM) ± SEM | Percent inhibition |
|------|-----------|----------------------|--------------------|
| 7g   | ![Chemical Structure](image1) | 14.49 ± 1.49 | 3.14 ± 0.41 |
| 7h   | ![Chemical Structure](image2) | 9.63 ± 1.21 | 2.94 ± 1.73 |
| 7i   | ![Chemical Structure](image3) | 29.62 ± | 2.20 ± 0.92 |
| 8a   | ![Chemical Structure](image4) | 13.4% | 15.6% |
| 8b   | ![Chemical Structure](image5) | 37.4% | 29.4% |
| 8c   | ![Chemical Structure](image6) | 6.74% | 35.4% |
| Code | Structure | ALR2 | ALR1 |
|------|-----------|------|------|
| 8d   | ![Structure](image1) | 31% 18.6% |
| 8e   | ![Structure](image2) | 1.52 ± 0.78 2.94 ± 1.34 |
| 8f   | ![Structure](image3) | 4.21 ± 1.63 12.4% |
| 8g   | ![Structure](image4) | 5.16% 23.5% |
| 8h   | ![Structure](image5) | 10.32% 33.4% |
| 8i   | ![Structure](image6) | 23.22% 12.5% |
group in the range from $\delta_H$ 10.78–10.83 and $\delta_H$ 11.51–10.55 ppm, respectively. The singlet of thiazoline $\text{-CH-}$ appeared in the range of $\delta_H$ 5.79–7.01 ppm. The other of different protons in all the series of thiazolines were in well agreement to confirm the structures of desired compounds. Moreover, the crystal structure of the compounds 5h and 7i further confirm the structure of thiazoline derivatives (Fig. 2, 3) (Table 1).

### 2.2 Biological activity
The synthetic thiazoline derivatives (5a–k, 6a–f, 7a–1 & 8a–j) were tested against aldehyde reductase enzyme (ALR1), and their anti-diabetic potential by evaluating inhibitory activity against aldose reductase (ALR2). Results indicated that out of thirty six compounds tested, eight of them, 5f, 6a, 6b, 6c, 7g, 7h, 7i, and 8e were found active inhibitors of ALR2 and ALR1.

| Code | Structure | ALR2 | ALR1 |
|------|-----------|------|------|
|      |           | IC_{50}(\mu M) ± SEM/Percent inhibition |      |
| 8j   |           | 34.83% | 27.8% |

Valproic acid$^b$
Sorbinil$^b$

$^a$ Half maximal inhibitory concentration. $^b$ Standard inhibitor.

Fig. 4 Selective ALR2 inhibitory activity of thiazoline derivatives (6d, 6e, 6f, 7a, 7b and 8f).
enzymes (Table 2). However, compound 6d, 6e, 6f, 7a, 7b, 7c and 8f were identified as selective ALR2 inhibitors (Fig. 4).

Compound 5f, one of the 2H-1,4-benzoxazin-3(4H)-one bearing derivatives were active against ALR1 and ALR2 having IC$_{50}$ value of 3.13 ± 1.45 µM and 3.24 ± 2.72 µM, respectively. The substitution of nitrophenyl with bromophenyl or chlorophenyl, as in compound 5b and 5j, showed weak activity against both ARL1 and ARL2 enzymes in comparison to sorbinil and valproic acid with respective IC$_{50}$ values of 3.14 ± 0.02 µM and 57.4 ± 0.89 µM (Table 2).

In general, compounds (6a–6f) containing adamantan substituent demonstrated the most promising activity among all the derivatives. Out of six, three compounds 6d, 6e and 6f showed a good inhibitory activity and selectively against ALR2 with IC$_{50}$ values 4.21 ± 2.35 µM, 2.18 ± 0.83 µM and 3.51 ± 2.31 µM respectively. Compounds 6a, 6b and 6c were also found to be active against ALR1 and ALR2 enzymes (Fig. 5).

Among the series, compound 7b showed high inhibition potential against ALR2 (IC$_{50}$ = 1.39 ± 2.21 µM). However, compound 7b was found to have considerably selective activity against ARL2 exhibiting only 23.4% inhibition against ALR1. The inhibition potential of chlorophenyl substituted thiazoline derivative 7i against ALR2 was much lower than the aforementioned compound with IC$_{50}$ of 38.2 ± 1.43 µM. Furthermore, an improved inhibitor potency of compound 7i was also observed against ALR1 (IC$_{50}$ 4.01 ± 0.39 µM).

Among the indolyl substituted thiazoline derivatives, compound 8e having a nitrophenyl moiety showed high

![Fig. 5 ALR1/ALR2 inhibitory activities of adamantyl substituted compounds 6a, 6b & 6c.](image)

![Fig. 6 Bioactivity of indolyl substituted thiazoline derivatives.](image)
inhibitory potency against ARL2 and ARL1, with IC\textsubscript{50} values of 1.52 ± 0.78 μM and 2.94 ± 1.34 μM respectively. However, the inhibitory activity of chlorophenyl substituted thiazoline derivative 8h, was weakened for both enzymes ALR2 and ALR1 demonstrating 10.32% and 33.4% inhibition respectively. Furthermore, the compound 8f was a selective ALR2 inhibitor than ALR1 exhibiting only 12.4% inhibition (Fig. 6). The other indolyl substituted compounds (8a, 8b, 8c, 8d, 8g, 8h, 8i, & 8j) were found inactive with less than 50% inhibitory activity against ALR2 as well against ARL1 enzymes.

3. Docking studies

3.1 Molecular docking studies of ALR1 and ALR2 inhibitors

To rationalize the mode of binding and nature of binding site interactions, molecular docking studies were carried out using BioSolveIT’s LeadIT software.\textsuperscript{36} For each inhibitor, the top 10 docked conformations were further evaluated for their binding free energy using HYDE utility (part of LeadIT software), the conformation with most favorable binding free energy was retained for further analysis. The crystal structures of porcine ALR1 (ref. 37) and human ALR2 (ref. 38) were downloaded from the Protein Data Bank [PDB ids: 3FX4 at 1.99 Å and 1U0S at 0.66 Å respectively].\textsuperscript{39} Docking protocol was validated by re-docking of the co-crystallized ligand. The docking protocol was able to reproduce the experimentally bound conformation of co-crystallized ligand (FX4) with an rmsd of 1.03. For docking against ALR1, three of the most active inhibitors 7h, 7i and 8e were selected. All compounds were found to bind in the same area of the binding pocket as the co-crystallized inhibitor FX4 (Fig. 7).

By analyzing the binding site interactions of the co-crystallized ligand (ALR1 inhibitor), FX4 ([5-(3-carboxymethoxy-4-methoxybenzylidene)-2,4-dioxothiazolidin-3-yl]acetic acid) it can be seen that the amino acid residues that are important for binding are Arg312, Phe298, Trp220, Trp22, Arg309, and Ala219. When docking studies of ALR1 inhibitors (7h, 7i, 8e) were carried out, same amino acids were found to be involved in binding these inhibitors (Table S1\textsuperscript{†}). Fig. S1\textsuperscript{†} shows the docked conformation of compound 7h. The oxygen atom of the benzodioxane ring was making hydrogen bond with Met302. The nitrogen atom of the C\textsubscript{N} moiety next to the thiazole ring was making a hydrogen bond with Arg312. The OH group of Tyr50 was acting as a hydrogen bond donor towards the fluorine atom. The carbonyl oxygen atom of Tyr 50 was acting as a halogen bond acceptor towards the chlorine atom. A number of hydrophobic interactions were also observed. Phe125 was making &pi;&ndash;&pi; stacked interactions with the thiazole and the phenyl ring attached to thiazole ring. Ile299 was making alkyl and &pi;&ndash;alkyl interactions with the methyl group and the phenyl ring of benzodioxane ring respectively. Ile49 was making &pi;&ndash;alkyl interactions with both chlorophenyl and fluorophenyl rings, whereas Trp114 was making pi-alkyl interaction with the methyl group.

Docking of compound 7i revealed hydrogen bonded interactions between the oxygen atom of the benzodioxane ring and

![Fig. 7 Overlap of ALR1 inhibitors 7h (dark pink), 7i (purple) and 8e (light pink) with the co-crystallized inhibitor FX4 ([5-(3-carboxymethoxy-4-methoxybenzylidene)-2,4-dioxothiazolidin-3-yl]acetic acid) (black). NADP is shown in grey.](image)

![Fig. 8 Docked conformation of ALR2 inhibitor 7b.](image)
Val300, and between the nitrogen atom of the C=N group and Met302 (Fig. S2†). A number of hydrophobic interactions were also observed. Ile299 was making alkyl and pi-alkyl interactions with the methyl group and phenyl ring of benzodioxane ring respectively. Pro301 was making also alkyl interaction with the methyl group. Lys23 was alkyl interaction with the chlorine atom and pi-alkyl interaction with chlorophenyl ring. Arg218 was making pi-alkyl interaction with the phenyl ring of benzodioxane ring, whereas Ala219 was making pi-alkyl interaction with the thiazole ring.

Docking of compound 8e revealed two hydrogen bonds of Arg309 and Arg312 with nitrogen atom of C=N bond and oxygen atom of the nitro group (Fig. S3†). Notable hydrophobic interactions include pi-sigma and pi-interaction of Ile49 with indole phenyl ring and pyrrole ring of indole respectively. Tyr50 was making pi–pi stacked interaction with pyrrole ring of indole. Ile299 and Met302 were making pi-alkyl interactions with thiazole ring and nitro phenyl ring respectively.

Docking studies of ALR2 inhibitors were also carried out for most active inhibitors 6e, 7b and 8e. Prior to docking, the docking protocol was verified by re-docking the co-crystallized ligand LDT ([[2-[(4-bromo-2-fluorobenzyl)carbamothioyl]-5-fluorophenoxy]acetic acid] from the ALR2 (PDB id: 1su0). The docking protocol was able to reproduce the experimentally observed conformation of LDT with rmsd of <2. Moreover all compounds were found to bind at the same region of the active site as that of the co-crystallized inhibitor LDT (Fig. S4†).

Docked conformation of compound 6e is shown in Fig. S5.† The nitrogen atom of the C=N group was making a hydrogen bond with Trp20. A number of hydrophobic interactions were observed that are deemed necessary for efficient binding. Leu300 was making a pi-sigma interaction with the chlorophenyl ring. Trp20 was making pi–pi stacked and pi-alkyl interactions with the benzyl ring and the methyl group respectively. Trp111 was making a pi-stacked interaction with the chlorophenyl ring and a pi-alkyl interaction with the chloro group. Two pi-sulfur interactions were also observed. Trp219 was making a pi-sulfur contact with the sulfur atom of the thiazole ring, whereas the sulfur atom of Cys298 was making pi-sulfur contact with the benzyl ring.

For compound 7b (Fig. 8), similar interactions were observed. Trp20 was within hydrogen bond distance (1.99 Å and 2.12 Å) of both nitrogen atoms of C=N groups. Hydrophobic interactions include Trp111 making a pi–pi stacked interaction with the bromo phenyl ring and a pi-alkyl interaction with the bromine atom. Trp20 was making a pi–pi T-shaped interaction with the thiazole ring. Pro218 was making a pi-alkyl interaction with the methyl group. Leu300 was making pi-alkyl interaction with both benzyl and bromo phenyl ring, whereas Val47 was making pi-alkyl interaction with the thiazole ring. A pi-sulfur interaction was also observed between Tyr48 and the sulfur atom of thiazole ring.

Docking of compound 8e was also carried out, its docked conformation along with binding site interactions are shown in Fig. 9. Both oxygen atoms of the nitro group were making hydrogen bonds with Trp111 and Tyr48, His110 is also within hydrogen bond distance to the nitro group. It is important to note that Trp111, Tyr48 and His110 are the same amino acids that are involved in binding the carboxylate group of standard inhibitor LDT. Leu300 was making hydrophobic interactions, pi-sigma and pi-alkyl with pyrrole ring of indole, and the phenyl indole ring respectively. Phe122 was making pi–pi T-shaped interaction with both thiazole and indole rings. Another pi–pi T-shaped interaction was observed between Trp20 and nitro phenyl ring. Moreover, an intramolecular pi–pi T-shaped contact was also observed between the nitro phenyl and benzyl ring, this orientation may additionally stabilize the binding of inhibitor. The nitro phenyl ring was also found to be involved in a pi-alkyl interaction with Val47. An electrostatic attractive interaction was observed between Lys77 and the oxygen atom of the nitro group. Another electrostatic (pi-anion) interaction was observed between Trp20 and same oxygen atom of the nitro group.
Fig. 10  Radius of gyration ($R_g$) of 1US0, protein plus cognate ligand (LDT) and protein plus selective compound (7b) during 50 ns MD-simulation run.

Fig. 11  Root mean square deviation (RMSD) of 1US0, protein plus cognate ligand (LDT) and protein plus selective compound (7b) during 50 ns MD-simulation run.

Fig. 12  Root mean square fluctuation (RMSF) of 1US0, protein plus cognate ligand (LDT) and protein plus selective compound (7b) during 50 ns MD-simulation run.
4. Molecular dynamics simulation

The conformational stabilities of the apoenzymes (ALR1 and ALR2) and their protein + ligand complexes, both cognate and test compounds, were performed to simulate protein flexibility. The structure of proteins (apoproteins) were first subjected to MD run of 50 ns and then docked poses of cognate ligands and selected ligands (holoenzymes) were submitted to MD run for 50 ns. The time evolution of the radius of gyration of 3FX4 and 1US0, apoenzymes and holoenzymes, exposed in the applied electric fields are shown in Fig. S6† and 10, respectively. The graph indicating that the average value of Rg slightly fluctuating between 1.92–1.97 nm for ALR1 (3FX4), while for ALR2 (1US0), the radius of gyration lies between 1.89 and 1.93 nm, signifying a fine degree of compactness. The average values of RMSD over a period 50 ns for 3FX4 and 1US0, apoenzymes and holoenzymes, exhibited minute fluctuations, reaffirming stable complex formation between enzymes and test compounds, as shown in Fig. S7† and 11, respectively. RMSF analyzes the portions of structure that are fluctuating from their mean structure the most (or least). The (RMSF) of ALR1 and ALR2 were examined, it was observed that residues were found stable in both the cases (Fig. S8,† and 12).

5. Conclusions

In this research, we have synthesized thiazoline derivatives (5a–k, 6a–f, 7a–1 & 8a–j), which were tested against aldehyde reductase (ALR1), and aldose reductase (ALR2) enzymes to study their anti-diabetic potential. The results demonstrated that compounds containing adamantyl substituent (6a–6f) have most promising activity among all the derivatives. The compound 7b (with benzyl substituent) among the series was found significantly selective against ARL2 with IC50 value of 1.39 ± 0.21 μM compare to sorbinil, a reference inhibitor, with IC50 values of 3.14 ± 0.02 μM. Furthermore, the compounds 6e also showed potency against ALR2 with IC50 values of 2.18 ± 0.83 μM, whilst 6f presented slightly higher with IC50 value of 3.51 ± 2.31 μM when compared with standard sorbinil. The compound 8e (with nitrophenyl substituent) demonstrated high potency and selectivity against ALR2 enzyme with IC50 values of 1.52 ± 0.78 μM. In silico molecular docking study was also performed to further study the putative binding of active compounds with the target enzyme to find lead compound for further steps of drug development.

6. Experimental section

6.1 General procedure for the synthesis of thiosemicarbazones (3)

A solution of corresponding aldehyde or ketone 1 (6-acetyl-2H-benzo[b][1,4]oxazin-3(4H)-one, 1-acetyl adamantane, 1,4-benzodioxan-6-yl methyl ketone and indole-3-carboxaldehyde; 0.01 mol) in methanol (10 mL) was added to a hot stirred solution of appropriate N1-substituted thiosemicarbazide 2 (0.01 mol) in methanol (10 mL). After adding few drops of glacial acetic acid as catalyst, the reaction mixture was heated under reflux for 2–6 h. Upon completion of reaction, monitored through TLC, the hot reaction mixture was cooled to room temperature. The solid product obtained in each case was filtered, washed several times with hot methanol and dried under vacuum to afford the desired thiosemicarbazones 3 in pure form. The resultant thiosemicarbazone derivatives were used as such in the next step without any further purification.

6.2 General procedure for the synthesis of thiazoline derivatives (5–8)

A mixture of equimolar amounts of appropriate thiosemicarbazone derivative 3 (0.005 mol), 4-substituted (bromo, nitro, chloro) phenacyl bromide 4 (0.005 mol) and anhydrous sodium acetate (0.005 mol) in absolute ethanol (25 mL) was heated under reflux with continuous stirring for 12–24 h. The reaction mixture was then partially concentrated on a rotary evaporator and left overnight. The precipitate formed in each case was filtered off, washed with warm diethyl ether, dried and recrystallized from absolute ethanol to furnish the target thiazoline derivatives 5–8 in pure form.

The different compounds are characterized as under:

6-[(E)-1-[(Z)-4-(4-bromophenyl)-3-phenylthiazol-2(3H)-ylidene) hydrazono]ethyl]-2H-benzo[b][1,4]oxazin-3(4H)-one (5a).

Yield 81%; m.p. 228–230 °C; IR v max (cm−1): 3188 (N=C), 3022 (Ar–H), 2942 (CH2), 1748 (C=O), 1581 (C=N), 1539, 1506 (Ar=C=C); 1H-NMR (DMSO-d6, 400 MHz) δ ppm: 2.13 (s, 3H, CH3–C=N), 4.60 (s, 2H, O–CH2–CO), 6.73 (s, 1H, CH= S), 6.96 (d, 1H, J = 8.4 Hz, Ar–H), 7.12 (d, 2H, J = 8.4 Hz, Ar–H), 7.28–7.36 (m, 4H, Ar–H), 7.38–7.39 (m, 2H, Ar–H), 7.43–7.47 (m, 3H, Ar–H), 10.80 (s, 1H, NH); 13C NMR (DMSO-d6, 100 MHz) δ ppm: 145.82 (CH3), 67.25 (OCH3), 103.11 (S=CH=), 113.79 (Ar=C), 116.30 (Ar–C), 121.58 (Ar=C), 122.14 (Ar=C), 127.55 (Ar=C), 128.21 (Ar=C), 128.88 (Ar=C), 129.29 (Ar=C), 130.53 (Ar=C), 131.73 (Ar=C), 133.19 (Ar=C), 138.11 (Ar=C), 138.79 (Ar=C), 144.59 (N=C=), 155.60 (C=N=N), 156.13 (C=N=C), 168.69 (HN=C=O); anal. calcd for C23H16BrN2O2S: 519.41: C, 57.81; H, 3.69; N, 10.79; found: C, 57.88; H, 3.65; N, 10.85.

6-[(E)-1-[(Z)-4-(4-bromophenyl)-3-(methoxyphenyl)thiazol-2(3H)-ylidene) hydrazono]ethyl]-2H-benzo[b][1,4]oxazin-3(4H)-one (5b).

Yield 84%; m.p. 276–278 °C; IR v max (cm−1): 3184 (N=C), 3018 (Ar–H), 2950 (CH3), 1690 (C=O), 1585 (C=N), 1536, 1509 (Ar=C=C); 1H-NMR (DMSO-d6, 400 MHz) δ ppm: 2.15 (s, 3H, CH3–C=N), 3.69 (s, 3H, OCH3), 4.59 (s, 2H, O–CH2–CO), 6.70 (s, 1H, CH–S), 6.75–6.77 (m, 1H, Ar–H), 6.86–6.88 (dd, 1H, J = 0.8 Hz, 8.4 Hz, Ar–H), 6.94–6.97 (m, 2H, Ar–H), 7.14 (d, 2H, J = 2.0 Hz, Ar–H), 7.25 (t, 1H, J = 8.0 Hz, Ar–H), 7.34 (dd, 1H, J = 2.4 Hz, 8.8 Hz, Ar–H), 7.42 (d, 1H, J = 2.0 Hz, Ar–H), 7.47 (d, 2H, J = 2.0 Hz, Ar–H), 10.78 (s, 1H, NH); 13C NMR (DMSO-d6, 100 MHz) δ ppm: 148.81 (CH3), 55.77 (OCH3), 67.25 (O-CH3), 103.14 (S=CH=), 113.81 (Ar=C), 113.98 (Ar=C), 114.74 (Ar–C), 116.31 (Ar–C), 120.87 (Ar=C), 122.13 (Ar=C), 127.56 (Ar=C), 129.87 (Ar=C), 130.43 (Ar=C), 130.71 (Ar=C), 131.73 (Ar=C), 133.19 (Ar=C), 133.79 (Ar=C), 139.09 (Ar=C), 144.61 (Ar=C), 155.70 (N=C=), 159.75 (C=N=N), 165.13 (C=N=C), 168.55 (HN=C=O); anal. calcd for C28H20BrN2O2S: 549.44: C, 56.84; H, 3.85; N, 10.20; found: C, 56.80; H, 3.89; N, 10.24.

© 2021 The Author(s). Published by the Royal Society of Chemistry

RSC Adv., 2021, 11, 17259–17282 | 17275
6-[(E)-1-[(Z)-(4-(4-bromophenyl)-3-(2,6-dimethylphenyl)thiazol-2(3H)-yldene) hydrazono)ethyl]-2H-benzo[b][1,4]oxazin-3(4H)-one (5c). Yield 80%; m.p. 260–262 °C; IR νmax (cm⁻¹): 3246 (N–H), 3049 (Ar–H), 2935 (CH₃), 1695 (C=O), 1583 (C=N), 1541, 1487 (Ar=C=C); ¹³C NMR (CDCl₃, 400 MHz) δ ppm: 1.70 (s, 6H, 2×CH₂Ar), 2.29 (s, 3H, CH₃–C=C–N), 4.76 (s, 2H, O–CH₂CO), 6.35 (s, 1H, CH–S), 7.06–7.10 (m, 3H, Ar–H), 7.17–7.19 (m, 2H, Ar–H), 7.27–7.31 (m, 1H, Ar–H), 7.42–7.74 (m, 2H, Ar–H), 7.49–7.51 (m, 1H, Ar–H), 7.54 (d, 1H, J = 2.0 Hz, Ar–H), 7.86 (s, 1H, NH); ¹³C NMR (DMSO-d₆, 100 MHz) δ ppm: 14.45 (CH₃), 18.25 (2×CH₂Ar), 67.43 (OCH₃), 100.90 (S–CH=), 113.29 (Ar=C), 116.37 (Ar=C), 122.43 (Ar=C), 125.81 (Ar=C), 128.51 (Ar=C), 128.74 (Ar=C), 128.85 (Ar=C), 128.95 (Ar=C), 131.48 (Ar=C), 134.07 (Ar=C), 136.54 (Ar=C), 139.23 (Ar=C), 144.28 (N=C–), 155.54 (C=N–N), 164.94 (N=C=O), 166.88 (HN=C=O); anal. calcld for C₂₂H₁₅BrN₂O₃S (515.54): C, 60.57; H, 4.11; N, 13.58; found: C, 60.51; H, 4.15; N, 13.52.

6-[(E)-1-[(Z)-(3-(4-fluorophenyl)-4-(4-nitrophenoxy)thiazol-2(3H)-yldene) hydrazono)ethyl]-2H-benzo[b][1,4]oxazin-3(4H)-one (5g). Yield 78%; m.p. 236–238 °C; IR νmax (cm⁻¹): 3338 (N=O), 3029 (Ar–H), 2964 (CH₃), 1659 (C=O), 1589 (C=N), 1557, 1508 (Ar=O=C); ¹³C NMR (DMSO-d₆, 400 MHz) δ ppm: 2.10 (s, 3H, CH₃–C=N), 4.60 (s, 2H, O–CH₂CO), 6.97 (s, 1H, CH–S), 7.05 (t, 2H, J = 8.8 Hz, Ar–H), 7.31–7.38 (m, 3H, Ar–H), 7.43 (d, 1H, J = 2.4 Hz, Ar–H), 7.82 (s, 1H, Ar–H), 8.76 (dd, 2H, J = 1.6 Hz, 6.8 Hz, Ar–H), 8.15 (dd, 2H, J = 2.0 Hz, 7.2 Hz, Ar–H), 10.83 (s, 1H, NH); ¹³C NMR (DMSO-d₆, 100 MHz) δ ppm: 14.81 (CH₃), 67.24 (OCH₃), 94.60 (S–CH=), 113.91 (Ar=C), 115.28 (Ar=C), 115.51 (Ar=C), 116.33 (Ar=C), 121.69 (Ar=C), 123.65 (Ar=C), 127.55 (Ar=C), 128.78 (Ar=C), 130.48 (Ar=C), 130.57 (Ar=C), 131.13 (Ar=C), 135.53 (Ar=C), 144.75 (Ar=C), 147.56 (Ar=C), 149.36 (Ar=C), 157.06 (N=C–), 159.27 (N=C–), 161.69 (C=N=O), 165.15 (N=C–N), 167.40 (HN=C=O); anal. calcld for C₁₂H₁₀F₂N₂O₃S (305.54): C, 59.64; H, 3.60; N, 13.91; found: C, 59.68; H, 3.64; N, 13.85.

6-[(E)-1-[(Z)-(2,6-dimethylphenyl)-4-(4-nitrophenoxy)thiazol-2(3H)-yldene) hydrazono)ethyl]-2H-benzo[b][1,4]oxazin-3(4H)-one (5h). Yield 81%; m.p. 218–220 °C; IR νmax (cm⁻¹): 3200 (N–H), 3022 (Ar–H), 2957 (CH₃), 1687 (C=O), 1587 (C=N), 1570, 1498 (Ar=C=C); ¹³C NMR (DMSO-d₆, 400 MHz) δ ppm: 2.07 (s, 3H, CH₃–C=N–N), 2.12 (s, 6H, 2×CH₂Ar), 4.60 (s, 2H, O–CH₂CO), 6.97 (d, 1H, J = 8.4 Hz, Ar–H), 7.06 (s, 1H, CH–S), 7.13–7.22 (m, 3H, Ar–H), 7.32–7.43 (m, 4H, Ar–H), 8.08 (dd, 2H, J = 2.0 Hz, 6.8 Hz, Ar–H), 10.78 (s, 1H, NH); ¹³C NMR (DMSO-d₆, 100 MHz) δ ppm: 14.69 (CH₃), 18.22 (2×CH₂Ar), 67.42 (OCH₃), 105.63 (S–CH=), 112.75 (Ar=C), 113.78 (Ar=C), 116.30 (Ar=C), 121.60 (Ar=C), 124.08 (Ar=C), 127.53 (Ar=C), 128.58 (Ar=C), 129.46 (Ar=C), 133.07 (Ar=C), 136.47 (Ar=C), 136.90 (Ar=C), 138.03 (Ar=C), 143.19 (Ar=C), 144.59 (Ar=C), 147.39 (N=C–), 155.78 (C=N–N), 165.11 (N=C–N), 166.58 (HN=C=O); anal. calcld for C₁₂H₁₀N₂O₃S (313.57): C, 61.34; H, 4.51; N, 13.64; found: C, 63.18; H, 4.54; N, 13.57.
C₂H₅ClNOS (474.96): C, 63.22; H, 4.03; N, 11.80; found: C, 63.25; H, 4.08; N, 10.76.

(6E)-1-[(2Z)-4-(4-chlorophenyl)-3-(3-methoxyphenyl)thiazol-2(3H)-ylidene] hydrazono-2H-benzo[b][1,4]oxazin-3(4H)-one (5j). Yield 79%; m. p. 228–230 °C; IR νmax (cm⁻¹): 3320 (N-H), 3045 (Ar-H), 2935 (CH₃), 1668 (C=O), 1593 (C=N), 1541, 1488 (Ar=C=C); ¹H-NMR (DMSO-d₆, 400 MHz) δ ppm: 2.13 (s, 3H, CH₃), 3.63 (s, 3H, OCH₃), 4.60 (s, 2H, O–CH₂-CO), 6.62–6.65 (m, 1H, Ar-H), 6.87–6.97 (m, 3H, CH–S, Ar-H), 7.08 (t, 1H, J = 8.0 Hz, Ar-H), 7.32–7.37 (m, 3H, Ar-H), 7.42 (d, 1H, J = 1.6 Hz, Ar-H), 7.53–7.56 (m, 2H, Ar-H), 7.57 (s, 1H, Ar-H), 10.82 (s, 1H, NH); ¹³C NMR (DMSO-d₆, 100 MHz) δ ppm: 14.89 (CH₃), 55.43 (OCH₃), 67.25 (O-CH₃), 95.04 (S=CH=), 111.65 (Ar-C), 113.89 (Ar-C), 114.01 (Ar-C), 116.31 (Ar-C), 120.33 (Ar-C), 121.66 (Ar-C), 127.54 (Ar-C), 128.41 (Ar-C), 128.89 (Ar-C), 129.11 (Ar-C), 132.97 (Ar-C), 133.22 (Ar-C), 140.62 (Ar-C), 141.33 (Ar-C), 144.69 (Ar-C), 156.69 (N=C=N), 159.11 (C=N=N), 165.15 (N=C=N), 167.17 (N=CH=O); anal. calc. for C₂₃H₁₂ClN₃O₄S (504.99): C, 61.84; H, 4.19; N, 11.09; found: C, 61.80; H, 4.24; N, 11.13.

(6E)-1-[(2Z)-4-(4-chlorophenyl)-3-(4-fluorophenyl)thiazol-2(3H)-ylidene] hydrazono-2H-benzo[b][1,4]oxazin-3(4H)-one (5k). Yield 78%; m. p. 230–232 °C; IR νmax (cm⁻¹): 3310 (N-H), 3064 (Ar-H), 2932 (CH₃), 1663 (C=O), 1587 (C=N), 1529, 1496 (Ar=C=C); ¹H-NMR (CDCl₃, 400 MHz) δ ppm: 2.08 (s, 3H, CH₃), 4.59 (s, 2H, O–CH₂-CO), 6.54–6.70 (m, 3H, CH–S, Ar-H), 7.28–7.34 (m, 5H, Ar-H), 7.41–7.42 (m, 1H, Ar-H), 7.54–7.57 (m, 5H, Ar-H), 10.81 (s, 1H, NH); ¹³C NMR (CDCl₃, 100 MHz) δ ppm: 14.78 (CH₃), 67.25 (O-CH₃), 94.76 (S=CH=), 100.04 (Ar-C), 113.89 (Ar-C), 115.34 (Ar-C), 116.31 (Ar-C), 127.54 (Ar-C), 128.45 (Ar-C), 129.18 (Ar-C), 130.41 (Ar-C), 130.49 (Ar-C), 133.20 (Ar-C), 141.08 (Ar-C), 144.70 (Ar-C), 156.74 (Ar-C), 159.48 (N=C=N), 161.62 (C=N=N), 165.15 (N=C=N), 167.50 (N=CH=O); anal. calc. for C₂₃H₁₁ClF₃N₂O₄S (520.92): C, 60.91; H, 3.68; N, 11.37; found: C, 60.95; H, 3.65; N, 11.32.

(2Z)-2-[(1-adamantan-1-yl)ethyldene]hydrazono-4-(4-bromophenyl)-3-(2,6-dimethylphenyl)-2,3-dihydrothiazole (6a). Yield 81%; m. p. 238–260 °C; IR νmax (cm⁻¹): 3049 (Ar-H), 2963 (CH₃), 1616 (C=N), 1541, 1487 (Ar=C=C); ¹H-NMR (CDCl₃, 400 MHz) δ ppm: 1.67–1.75 (m, 6H, adamantane –CH₃), 1.81 (m, 6H, adamantane –CH₃), 1.85 (s, 3H, CH₃–C=–N), 2.01–2.02 (bs, 3H, adamantane –CH₃), 6.11 (s, 1H, CH–S), 6.95 (d, 2H, J = 8.8 Hz, Ar-H), 7.19–7.21 (m, 3H, Ar-H), 7.27–7.31 (m, 4H, Ar-H); ¹³C NMR (CDCl₃, 100 MHz) δ ppm: 12.48 (CH₃), 28.46 (adamantane-C), 36.98 (adamantane-C), 39.94 (adamantane-C), 40.38 (adamantane-C), 102.08 (S=CH=), 122.24 (Ar-C), 127.39 (Ar-C), 128.21 (Ar-C), 128.69 (Ar-C), 129.45 (Ar-C), 130.55 (Ar-C), 131.43 (Ar-C), 136.08 (Ar-C), 137.97 (N=C=N), 167.51 (C=N=N), 169.44 (N=C=N); anal. calc. for C₂₇H₂₃BrN₂S (560.50): C, 64.03; H, 5.57; N, 8.30; found: C, 64.10; H, 5.52; N, 8.34.

(2Z)-2-[(1-adamantan-1-yl)ethyldene]hydrazono-4-(4-bromophenyl)-3-(naphthalen-1-yl)-2,3-dihydrothiazole (6b). Yield 90%; m. p. 300 °C; IR νmax (cm⁻¹): 3035 (Ar-H), 2941 (CH₃), 1616 (C=N), 1545, 1507 (Ar=C=C); ¹H-NMR (CDCl₃, 400 MHz) δ ppm: 1.54 (s, 3H, CH₃–C=–N), 1.65–1.70 (m, 6H, adamantane –CH₃), 1.73–1.77 (bs, 6H, adamantane –CH₂), 2.00 (bs, 3H, adamantane –CH₂), 6.18 (s, 1H, CH–S), 6.89 (dd, 2H, J = 2.0 Hz, 6.8 Hz, Ar-H), 7.13 (dd, 2H, J = 2.0 Hz, 6.8 Hz, Ar-H), 7.22 (dd, 1H, J = 1.2 Hz, 7.2 Hz, Ar-H), 7.36 (t, 1H, J = 7.6 Hz, Ar-H), 7.47–7.50 (m, 2H, Ar-H), 7.77–7.89 (m, 3H, Ar-H); ¹³C NMR (CDCl₃, 100 MHz) δ ppm: 12.24 (CH₃), 28.43 (adamantane-C), 36.96 (adamantane-C), 39.86 (adamantane-C), 40.26 (adamantane-C), 97.91 (S=CH=), 123.84 (Ar-C), 125.34 (Ar-C), 126.31 (Ar-C), 126.72 (Ar-C), 127.18 (Ar-C), 128.26 (Ar-C), 128.82 (Ar-C), 129.04 (Ar-C), 131.26 (Ar-C), 134.27 (Ar-C), 135.09 (Ar-C), 136.87 (Ar-C), 153.58 (N=C=N), 166.17 (C=N=N), 169.88 (N=C=N); anal. calc. for C₃₁H₂₃BrN₃S (556.56): C, 66.90; H, 5.43; N, 7.55; found: C, 66.95; H, 5.45; N, 7.52.
C25H20BrN3O2S (506.41): C, 59.29; H, 3.98; N, 8.30; found: C, 59.35; H, 3.95; N, 8.34.

(2Z)-2-((1-adamantan-1-yl)ethyldiene)hydrazono)-3(2,6-dimethylphenyl)-2,3-dihydrothiazole (6f). Yield 82%; m.p. 160–162 °C; IR νmax (cm−1): 3055 (Ar–H), 2975 (CH3), 1604 (C=O); 1H-NMR (CDCl3, 400 MHz) δ ppm: 1.65–1.69 (6H, 2×CH2), 1.74 (s, 3H, CH3–C=C), 1.78–1.79 (bs, 6H, adamantane–CH3), 2.10 (bs, 3H, CH3–C=C), 2.13 (s, 6H, 2×CH3–Ar), 6.08 (s, 1H, CH–S), 6.96–7.00 (m, 4H, Ar-H), 7.08–7.10 (m, 3H, Ar-H); 13C NMR (DMSO-d6, 100 MHz) δ ppm: 12.37 (CH3), 18.36 (2×CH2–Ar), 28.46 (adamantan-3-yl), 36.98 (adamantan-4-yl), 40.28 (adamantan-1-yl), 100.75 (S-CH2), 102.25 (S-CH2); 1H-NMR (DMSO-d6, 100 MHz) δ ppm: 2.05 (s, 3H, CH3–Ar), 4.16 (s, 4H, (OCH2CH2O)$_2$), 6.16 (s, 1H, CH–S), 6.85 (d, 1H, J = 8.4 Hz, Ar-H), 6.96–7.00 (m, 2H, Ar-H), 7.22–7.27 (m, 3H, Ar-H), 7.30–7.33 (m, 3H, Ar-H), 7.34–7.38 (m, 1H, Ar-H), 7.40 (d, 1H, J = 2.4 Hz, Ar-H); 13C NMR (DMSO-d6, 100 MHz) δ ppm: 14.63 (CH3), 64.33 (O–CH3), 64.56 (O–CH3), 102.25 (S–CH2), 115.33 (Ar–C), 116.85 (Ar–C), 119.86 (Ar–C), 122.37 (Ar–C), 127.40 (Ar–C), 128.30 (Ar–C), 128.72 (Ar–C), 129.53 (Ar–C), 131.48 (Ar–C), 132.75 (Ar–C), 137.90 (Ar–C), 138.90 (Ar–C), 143.14 (Ar–C), 144.47 (N–C=), 156.72 (C=N–N), 168.36 (N=C=N); anal. calcd for C28H30ClN3S (476.08): C, 71.01; H, 6.58; N, 8.57; found: C, 71.01; H, 6.62; N, 8.53.

(Z)-4-(4-bromophenyl)-2-((E)-2-(1,2,3-dihydrobenzo[b][1,4]dioxin-6-yl) ethyldiene) hydrazono)-3-(2,6-dimethylphenyl)-2,3-dihydrothiazole (7a). Yield 82%; m.p. 160–162 °C; IR νmax (cm−1): 3055 (Ar–H), 2975 (CH3), 1604 (C=O); 1H-NMR (CDCl3, 400 MHz) δ ppm: 2.23 (s, 3H, CH3–C=C–N), 4.27 (s, 4H, –OCH2CH2O–), 6.16 (s, 1H, CH–S), 6.85 (d, 1H, J = 8.4 Hz, Ar-H), 6.96–7.00 (m, 2H, Ar-H), 7.22–7.27 (m, 3H, Ar-H), 7.30–7.33 (m, 3H, Ar-H), 7.34–7.38 (m, 1H, Ar-H), 7.40 (d, 1H, J = 2.4 Hz, Ar-H); 13C NMR (DMSO-d6, 100 MHz) δ ppm: 11.07 (CH3), 18.36 (2×CH2–Ar), 28.46 (adamantan-3-yl), 36.98 (adamantan-4-yl), 40.28 (adamantan-1-yl), 100.75 (S-CH2), 102.25 (S-CH2); 1H-NMR (DMSO-d6, 100 MHz) δ ppm: 2.05 (s, 3H, CH3–Ar), 4.16 (s, 4H, (OCH2CH2O)$_2$), 6.16 (s, 1H, CH–S), 6.85 (d, 1H, J = 8.4 Hz, Ar-H), 6.96–7.00 (m, 2H, Ar-H), 7.22–7.27 (m, 3H, Ar-H), 7.30–7.33 (m, 3H, Ar-H), 7.34–7.38 (m, 1H, Ar-H), 7.40 (d, 1H, J = 2.4 Hz, Ar-H); 13C NMR (DMSO-d6, 100 MHz) δ ppm: 14.63 (CH3), 64.33 (O–CH3), 64.56 (O–CH3), 102.25 (S–CH2), 115.33 (Ar–C), 116.85 (Ar–C), 119.86 (Ar–C), 122.37 (Ar–C), 127.40 (Ar–C), 128.30 (Ar–C), 128.72 (Ar–C), 129.53 (Ar–C), 131.48 (Ar–C), 132.75 (Ar–C), 137.90 (Ar–C), 138.90 (Ar–C), 143.14 (Ar–C), 144.47 (N–C=), 156.72 (C=N–N), 168.36 (N=C=N); anal. calcd for C28H30ClN3S (476.08): C, 71.01; H, 6.58; N, 8.57; found: C, 71.01; H, 6.62; N, 8.53.
[1H,3H]-Ar-H), 7.19 ppm: 2.21 (s, 3H, CH3-C= N), 4.25 (s, 4H, -OCH2CH2O-), 6.13 (s, 1H, CH-S), 6.83 (d, 1H, J = 8.4 Hz, Ar-H), 7.01-7.03 (m, 2H, 2H, Ar-H), 7.13-7.15 (m, 2H, Ar-H), 7.20-7.23 (m, 3H, Ar-H), 7.28-7.36 (m, 3H, Ar-H), 7.39 (d, 1H, J = 2.0 Hz, Ar-H); 13C NMR (DMso-d6, 100 MHz) δ ppm: 14.72 (CH3), 64.33 (O-CH3), 64.56 (O-CH3), 102.19 (S=C=H), 115.33 (Ar-C), 116.86 (Ar-C), 119.86 (Ar-C), 127.40 (Ar-C), 128.31 (Ar-C), 128.53 (Ar-C), 128.72 (Ar-C), 129.29 (Ar-C), 129.93 (Ar-C), 132.75 (Ar-C), 137.89 (Ar-C), 143.13 (Ar-C), 144.47 (N=C=), 156.69 (C=N=), 164.80 (N=C=N=); anal. calc'd for C26H16Cl2N2O4S4: C, 65.00; H, 4.36; N, 9.10; found: C, 65.04; H, 4.31; N, 9.16.

**Z-(4-(4-chlorophenyl)-2-((E)-1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)ethylidene-3-phenyl-2,3-dihydrothiazole (7g).** Yield 81%; m.p. 170-172 °C; IR νmax (cm⁻¹): 3050 (Ar-H), 2984 (CH3), 1596 (C=C-N), 1560, 1517 (C=O); 1H-NMR (CDC13, 400 MHz) δ ppm: 2.12 (s, 3H, CH3-C= N), 4.25 (s, 4H, -OCH2CH2O-), 6.13 (s, 1H, CH-S), 6.82 (d, 1H, J = 8.4 Hz, Ar-H), 6.96-7.02 (m, 4H, Ar-H), 7.15-7.19 (m, 4H, Ar-H), 7.34 (dd, 1H, J = 2.4 Hz, 8.8 Hz, Ar-H) 7.39 (d, 1H, J = 2.0 Hz, Ar-H); 13C NMR (DMso-d6, 100 MHz) δ ppm: 14.69 (CH3), 64.33 (O-CH3), 64.56 (O-CH3), 102.21 (S=C=H), 115.34 (Ar-C), 115.62 (Ar-C), 115.84 (Ar-C), 116.88 (Ar-C), 119.87 (Ar-C), 128.67 (Ar-C), 129.35 (Ar-C), 129.65 (Ar-C), 129.94 (Ar-C), 130.93 (Ar-C), 132.63 (Ar-C), 134.15 (Ar-C), 144.54 (Ar-C), 156.92 (Ar-C), 160.08 (N=C=), 162.54 (C=N=), 168.33 (N=C=N); anal. calc'd for C26H16Cl2F2N2O4S4: C, 62.56; H, 3.99; N, 8.76; found: C, 62.63; H, 3.92; N, 8.84.

**Z-(3-benzyl-4-(4-chlorophenyl)-2-((E)-1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)ethylidene-3-phenyl-2,3-dihydrothiazole (7i).** Yield 84%; m.p. 150-152 °C; IR νmax (cm⁻¹): 3012 (Ar-H), 2960 (CH3), 1602 (C=N), 1578, 1507 (Ar-C=C); 1H-NMR (CDCl3, 400 MHz) δ ppm: 2.27 (s, 3H, CH3-C=N), 4.25 (s, 4H, -OCH2CH2O-), 5.00 (s, 2H, -CH2-), 5.92 (s, 1H, CH-S), 6.82 (d, 1H, J = 8.4 Hz, Ar-H), 7.05-0.07 (m, 2H, Ar-H), 7.10-7.12 (m, 2H, Ar-H), 7.19-7.23 (m, 3H, Ar-H), 7.26-7.28 (m, 2H, Ar-H) 7.37 (dd, 1H, J = 2.0 Hz, 8.4 Hz, Ar-H) 7.40 (d, 1H, J = 2.4 Hz, Ar-H); 13C NMR (DMso-d6, 100 MHz) δ ppm: 14.46 (CH3), 49.28 (CH3), 64.34 (O-CH3), 64.56 (O-CH3), 100.74 (S=C=H), 115.23 (Ar-C), 116.87 (Ar-C), 119.76 (Ar-C), 127.16 (Ar-C), 127.26 (Ar-C), 128.43 (Ar-C), 128.81 (Ar-C), 130.33 (Ar-C), 132.92 (Ar-C), 137.18 (Ar-C), 139.45 (Ar-C), 143.16 (Ar-C), 144.33 (N=C=), 155.67 (C=N=), 168.58 (N=C=); anal. calc'd for C24H16Cl2N2O4S4: C, 65.61; H, 4.66; N, 8.83; found: C, 65.69; H, 4.61; N, 8.87.

**Z-(2-(E)-1(1H-indol-3-yl)methylene)hydrazono-4-(4-fluorophenyl)-3-phenyl-2,3-dihydrothiazole (8a).** Yield 80%; m.p. 296-298 °C; IR νmax (cm⁻¹): 3297 (N-H), 3041 (Ar-H), 1615 (C=N), 1553, 1499 (Ar-C=C); 1H-NMR (Acetone + DMso-d6, 400 MHz) δ ppm: 6.93 (s, 1H, CH-S), 7.18-7.22 (m, 2H, Ar-H), 7.33-7.35 (m, 3H, Ar-H), 7.39-7.46 (m, 5H, Ar-H, CH=N), 7.71 (d, 1H, J = 2.8 Hz, Ar-H), 8.10 (dd, 2H, J = 2.0 Hz, 7.2 Hz, Ar-H), 8.26-8.29 (1H, Ar-H), 8.39 (s, 1H, indole CH), 11.54 (s, 1H, NH); 11C NMR (DMso-d6, 100 MHz) δ ppm: 105.86 (S=C=H), 112.34 (Ar-C), 112.90 (Ar-C), 120.98 (Ar-C), 122.49 (Ar-C), 123.00 (Ar-C), 123.92 (Ar-C), 124.92 (Ar-C), 128.32 (Ar-C), 128.96 (Ar-C), 129.34 (Ar-C), 129.54 (Ar-C), 130.97 (Ar-C), 137.58 (Ar-C), 137.66 (Ar-C), 138.05 (Ar-C), 138.14 (Ar-C), 147.10 (N=C=), 149.73 (C=N=N),
166.81 (N–C=–N); anal. cded for C_{24}H_{16}N_{2}O_{2}S (439.49): C, 65.59; H, 3.90; N, 15.94; found: C, 65.55; H, 3.95; N, 15.90.

(2E)-(1H-indol-3-yl)methylene]hydrazono]-3-benzyl-4-(4-chlorophenyl)-2,3-dihydrothiazole (8e).

(2E)-(1H-indol-3-yl)methylene]hydrazono]-3-benzyl-4-(4-chlorophenyl)-2,3-dihydrothiazole (8f).

(2E)-(1H-indol-3-yl)methylene]hydrazono]-4-(4-chlorophenyl)-3-phenyl-2,3-dihydrothiazole (8g).

Conflicts of interest

The authors declare no conflict of interest.

Acknowledgements

Z. S. is thankful to Higher Education Commission, Islamabad, Pakistan through Project No. NRPU/6975 for financial support.

References

1. R. Khursheed, S. K. Singh, S. Wadhwa, B. Kapoor, M. Gulati, R. Kumar, A. K. Ramanuny, A. Awasthi and K. Dua, Treatment strategies against diabetes: Success so far and challenges ahead, Eur. J. Pharmacol., 2019, 862, 172625.

2. A. D. Association, 12. Older adults: standards of medical care in diabetes—2019, Diabetes Care, 2019, 42, S139–S147.
bearing an imidazo [2, 1-b] thiazole moiety, Turk. J. Pharm. Sci., 2019, 16, 1.
17. B. Sever, M. D. Altıntop, Y. Demir, M. Pekdoğan, G. A. Çiftçi, Ş. Beydemir and A. Özdemir, An extensive research on aldose reductase inhibitory effects of new 4H-1, 2, 4-triazole derivatives, J. Mol. Struct., 2021, 1224, 129446.
18. S. Miyamoto, Recent advances in aldose reductase inhibitors: potential agents for the treatment of diabetic complications, Expert Opin. Ther. Pat., 2002, 12, 621–631.
19. K. Sturm, L. Levstik, V. J. Demopoulos and A. Kristl, Permeability characteristics of novel aldose reductase inhibitors using rat jejenum in vitro, Eur. J. Pharm. Sci., 2006, 28, 128–133.
20. M. T. Shehzad, A. Imran, G. S. S. Njateng, A. Hameed, M. Islam, M. al-Rashida, M. Uroos, A. Asari, Z. Shafiq and M. Iqbal, Benzoazinone-thiosemicarbazones as anti diabetic leads via aldose reductase inhibition: Synthesis, biological screening and molecular docking study, Bioorg. Chem., 2019, 87, 857–866.
21. M. Kumar, S. Choudhary, P. K. Singh and O. Silakari, Addressing selectivity issues of aldose reductase 2 inhibitors for the management of diabetic complications, Future Med. Chem., 2020, 12, 1327–1358.
22. F. C. Wouters, J. Gershenzon and D. G. Vassão, Benzoazinoids: reactivity and modes of action of a versatile class of plant chemical defenses, J. Braz. Chem. Soc., 2016, 27, 1379–1397.
23. W. G. Lima, F. J. dos Santos, A. Cristina Soares, F. A. Macias, J. M. Molinillo, J. Maria Siqueira Ferreira and J. Máximo de Siqueira, Synthesis and antimicrobial activity of some benzoazinoid derivatives of 2-nitrophenol and 3-hydroxy-2-nitropyridine, Synth. Commun., 2019, 49, 286–296.
24. B. P. Marasini, F. Rahim, S. Perveen, A. Karim, K. M. Khan and M. I. Choudhary, Synthesis, structure-activity relationships studies of benzoazinone derivatives as x-chymotrypsin inhibitors, Bioorg. Chem., 2017, 70, 210–221.
25. N. Kolocouris, G. Zoidis, G. B. Fytas, S. R. Prathalingham, J. M. Kelly, L. Naens and E. De Clercq, Design and synthesis of bioactive adamantane spiro heterocycles, Bioorg. Med. Chem. Lett., 2007, 17, 4358–4362.
26. G. Zoidis, N. Kolocouris, J. M. Kelly, S. R. Prathalingham, L. Naens and E. De Clercq, Design and synthesis of bioactive adamantaminoalcohols and adamantamamines, Eur. J. Med. Chem., 2010, 45, 5022–5030.
27. L. I. Pilkington and D. Barker, Synthesis and biology of 1,4-benzodioxane lignan natural products, Nat. Prod. Rep., 2015, 32, 1369–1388.
28. L. I. Pilkington, J. Wagoner, S. J. Polyak and D. Barker, Enantioselective synthesis, stereochemical correction, and biological investigation of the rodgersinine family of 1,4-benzodioxane neolignans, Org. Lett., 2015, 17, 1046–1049.
29. A. Özdemir, M. D. Altıntop, G. Turan-Zitouni, G. A. Çiftçi, İ. Ertorun, Ö. Alataş and Z. A. Kaplançik, Synthesis and evaluation of new indole-based chalcones as potential antiinflammatory agents, Eur. J. Med. Chem., 2015, 89, 304–309.
30 S. D. Shamon and M. I. Perez, Blood pressure-lowering efficacy of reserpine for primary hypertension, *Cochrane Database Syst. Rev.*, 2016, **12**, CD007655.

31 E. Westermann, ANN, Cumulative effects of reserpine on the pituitary-adrenocortical and sympathetic nervous system, *Drugs and Enzymes*, 2013, **3**, 381–392.

32 S. Bindu, K. Rameshkumar, B. Kumar, A. Singh and C. Anilkumar, Distribution of reserpine in Rauvolia species from India–HPTLC and LC–MS studies, *Ind. Crops Prod.*, 2014, **62**, 430–436.

33 M. T. Shehzad, A. Khan, M. Islam, S. A. Halim, M. Khiat, M. U. Anwar, J. Hussain, A. Hameed, A. R. Pasha, F. A. Khan, A. Al-Harrasi and Z. Shafiq, Synthesis, characterization and molecular docking of some novel hydrazonothiazolines as urease inhibitors, *Bioorg. Chem.*, 2020, **94**, 103404.

34 M. T. Shehzad, A. Hameed, M. Al-Rashida, A. Imran, M. Uroos, A. Asari, H. Mohamad, M. Islam, S. Iftikhar, Z. Shafiq and J. Iqbal, Exploring antidiabetic potential of adamantyl-thiosemicarbazones via aldose reductase (ALR2) inhibition, *Bioorg. Chem.*, 2019, **92**, 103244.

35 M. T. Shehzad, A. Khan, M. Islam, A. Hameed, M. Khiat, S. A. Halim, M. U. Anwar, S. R. Shah, J. Hussain, R. Csuk, S. Khan, A. Al-Harrasi and Z. Shafiq, Synthesis and urease inhibitory activity of 1, 4-benzodioxane-based thiosemicarbazones: Biochemical and computational approach, *J. Mol. Struct.*, 2020, **1209**, 127922.

36 J. Gao, Z. Tian and X. Yang, Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies, *BioSci. Trends*, 2020, **14**(1), 72–73.

37 V. Carbone, M. Giglio, R. Chung, T. Huyton, J. Adams, R. Maccari, R. Ottana, A. Hara and O. El-Kabbani, Structure of aldehyde reductase in ternary complex with a 5-arylidene-2, 4-thiazolidinedione aldose reductase inhibitor, *Eur. J. Med. Chem.*, 2010, **45**, 1140–1145.

38 E. Howard, R. Sanishvili, R. Cachau, A. Mitschler, B. Chevrier, P. Barth, V. Lamour, M. Van Zandt, E. Sibley and C. Bon, Ultrahigh resolution drug design I: Details of interactions in human aldose reductase–inhibitor complex at 0.66 Å, *Proteins: Struct., Funct., Bioinf.*, 2004, **55**, 792–804.

39 RCSB Protein Data Bank, in *RCSB Protein Data Bank*, http://www.rcsb.org, (accessed June, 2018).